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Abstract Background:Medication safety research and clinical pharmacy practice today
is primarily focused on managing preventable adverse drug events (pADEs).
Determinants of both pADEs and non-preventable adverse drug reactions
(ADRs) have been identified. However, relatively little is known on the
overlap between these determinants and the balance of preventable and non-
preventable harm inpatients experience in modern computerized hospitals.
Objective: The aim of this study was to analyse the prevalence of pADEs and
non-preventable ADRs as well as the determinants, including multimorbidity,
of these ADEs, i.e. both pADEs and ADRs.
Methods: Adverse events experienced by patients admitted to two Dutch
hospitals with functioning computerized physician order entry (CPOE) sys-
tems were prospectively identified through chart review. Adverse events were
divided into pADEs (i.e. as a result of a medication error) and non-
preventable ADRs. In both cases, a causal relationship between adverse
events and patients’ drugs was established using the simplified Yale algo-
rithm. Study data were collected anytime between April 2006 and May 2008
over a 5-month period at each hospital ward included in the study, beginning
from 8 weeks after CPOE was implemented at the ward.
Results: pADEs and non-preventable ADRs were experienced by 349 (58%)
patients, of whom 307 (88%) had non-preventable ADRs. Multimorbidity
(adjusted odds ratio [ORadj] 1.90; 95%CI 1.44, 2.50; ORadj 1.28; 95%CI 1.14,
1.45, respectively), length of stay (ORadj 1.13; 95% CI 1.06, 1.21; ORadj 1.11;
95% CI 1.07, 1.16, respectively), admission to the geriatric ward (ORadj 7.78;
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95% CI 2.15, 28.13; ORadj 3.82; 95% CI 1.73, 8.45, respectively) and number
of medication orders (ORadj 1.25; 95%CI 1.16, 1.35; ORadj 1.13; 95%CI 1.06,
1.21, respectively) were statistically significantly associated with pADEs and
ADRs. Admission to the gastroenterology/rheumatology ward (ORadj 0.22;
95% CI 0.06, 0.77; ORadj 0.40; 95% CI 0.24, 0.65, respectively) was inversely
related to both pADEs and ADRs. Other determinants for ADRs only were
female sex (ORadj 1.77; 95% CI 1.12, 2.80) and use of drugs affecting the
nervous system (ORadj 1.83; 95% CI 1.09, 3.07). Age was a significant deter-
minant for pADEs only (ORadj 1.07; 95% CI 1.03, 1.11).
Conclusions: In this study more than half of the patients admitted to the
hospitals are harmed by drugs, of which most are non-serious, non-
preventable ADRs (after the introduction of CPOE). Determinants of both
pADEs and ADRs overlap to a large extent. Our results imply the need
for signalling early potential adverse events that occur during the normal
use of drugs in multimorbid patients or those in geriatric wards. Subsequent
therapeutic interventions may improve the well-being of hospitalized pa-
tients to a greater extent than focusing on errors in the medication process
only.
Background
Medication safety research and clinical phar-
macy practice today is primarily focused on man-
aging preventable adverse drug events (pADEs).
[1]
These types of adverse drug events (ADEs) are
caused, by definition, by errors in the medication
process. However, most of these medication er-
rors do not result in ADEs.[2] The introduction
of computerized physician order entry (CPOE)
and clinical decision support systems (CDSS)
has been successful in reducing the number of
medication errors;[3-7] however, this has inversely
affected the attention given to the management of
non-preventable adverse drug reactions (ADRs)
that occur during correct use of medication.
Although ADRs are non-preventable in nature,
their outcome may be modified by early
detection.[8,9]
Most studies focus on more serious ADEs
that, for example, prolong hospital stay.[10,11] A
recent study in Drug Safety showed that 0.9% of
hospital admissions resulted in serious ADEs, of
which approximately 20% were considered pre-
ventable.[11] Nevertheless, non-serious ADEs also
affect the well-being of hospitalized patients, and
timely identification may improve patients’ well-
being.[12] Determinants for the occurrence of
pADEs and ADRs have been studied in the past
and even risk scores have been developed.[10,13-16]
The potential relationship between age, sex, length
of hospital stay, number and type of drugs and
the occurrence of ADEs have been commonly
studied.[15-18] Although results vary for these de-
terminants, the number and type of drugs (e.g.
drugs affecting the cardiovascular system, blood
and blood forming organs, nervous system, anti-
infectives, etc.) are consistently mentioned as
significant determinants for ADEs.[15-18] How-
ever, less is known about multimorbidities (i.e.
underlying clinical conditions) as a determinant
of a patient’s vulnerability to experience ADEs.
Most studies of determinants have focused, to
date, on their relationship with either pADEs or
ADRs, or both combined. Rarely have both
pADEs and ADRs been studied separately in one
study setting.
In this study, we determine the prevalence
of pADEs versus non-preventable ADRs and
identify important determinants for both types of
medication harm in a hospital setting with CPOE/
CDSS.
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Methods
Design
A prospective chart review study was per-
formed as a substudy of a larger study looking at
the impact of implementation of a CPOE system
and CDSS on medication errors and pADEs.[4]
The current study uses data that were collected
over a 5-month period that started 8 weeks after
CPOE was implemented (post-implementation).
CPOE was implemented at different points be-
tween 2006 and the end of 2007 in different hos-
pital wards involved in the study; subsequently,
data collection took place between April 2006 (start
of data collection in the first ward) and May 2008
(end of data collection from the last ward), as de-
scribed in detail previously by vanDoormaal et al.[4]
Setting and Study Population
The study was performed in the University
Medical Center Groningen (UMCG) and Twee-
Steden Hospital, Tilburg and Waalwijk, the
Netherlands. Patients admitted for more than
24 hours to the geriatric and general internal med-
icine wards of TweeSteden Hospital and the gen-
eral internal medicine and gastroenterology/
rheumatology wards in the UMCGwere included
in the study. Since the objective of this study fell
within the boundaries of normal hospital care
and quality of care improvement, a waiver from
the Medical Ethics Committee was obtained.
Patients received information about the study,
after which they could object to inclusion.
Computerized Physician Order Entry Systems
The CPOE systems implemented in our hos-
pitals have a ‘basic’ CDSS that checks drug-drug
interactions (DDIs) and basic dosing guidance.[19]
In the UMCG, the commercially available system
Medicator (iSOFT, Leiden, the Netherlands)
was used. In this system, only the process of or-
dering medication is computerized; the process of
dispensing and administering the medication is
still paper-based. In TweeStedenHospital, Theriak
(Theriak evf, Tilburg, the Netherlands), a partly
locally-developed system is used in which the
process of patient identification and medication
administration is also automated by scanning
barcodes on patients’ wristbands, and barcodes
on the packaging of medication.
Data Collection
Data were prospectively collected during daily
ward visits by research pharmacists (AD, JvD and
RZ). Weekend data were collected on Mondays.
Patient characteristics (age, sex, weight, height and
co-morbidities), disease characteristics (medical
history, reason for admission and differential di-
agnoses), drugs used and laboratory results were
extracted by reviewing physicians’ and nurses’
charts, the CPOE system and the hospital in-
formation system. Co-morbidities and diagnoses
were recorded following the International Classi-
fication of Diseases, 10th revision (ICD-10).[20]
Drugs were classified using the Anatomical Ther-
apeutic Chemical (ATC) classification system.[21]
Outcomes and Assessment of Preventable
Adverse Drug Events (pADEs) and Adverse
Drug Reactions (ADRs)
The primary outcome parameters were the
prevalence of pADEs and ADRs. All adverse
events (i.e. untoward medical occurrences not
necessarily related to the treatment) were col-
lected. In daily ward visits, all signs and symp-
toms that could possibly be related to medication
use recorded in the physicians’ and nurses’ charts
were included. Adverse events were classified by
the research pharmacists according to WHO
Adverse Reaction Terminology.[22] In this classi-
fication, certain adverse events are classified as
‘critical terms’; these adverse events refer to, or
are possibly indicative of, ‘serious disease states,
which have been regarded as particularly im-
portant and should be evaluated further’.
Subsequently, a two-step procedure was used
to identify any pADEs; remaining ADEs were
then assessed to determine relationship to use of a
drug, as described in the following section.
pADEs
A pADE was defined as an adverse event re-
lated to both a drug and a medication error, as
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assessed in the framework of our previously-
described intervention study.[4] In brief, after data
collection of all possible adverse events, the re-
search pharmacists (AD, JvD and RZ) reviewed
and classified all medication orders of all in-
cluded patients using the classification scheme
developed by the Netherlands Association of
Hospital Pharmacists.[23] The classification dis-
tinguishes prescribing, transcribing, dispensing,
administering and ‘across settings’ errors. In this
study, only prescribing and transcribing errors
were recorded. Prescribing errors were subclassified
as administrative errors (errors on readability,
patient data, ward and prescriber data, drug
name, dosage form and route of administration),
dosing errors (errors on strength, dosage, fre-
quency, length of therapy and directions for use)
and therapeutic errors (DDIs, contraindications,
incorrect monotherapy, duplicate therapy, ther-
apeutic drug monitoring or laboratory monitor-
ing errors). Transcribing errors were defined as
errors in interpretation, verification and tran-
scription of medication orders. The severity of all
identified medication errors was assessed using
the National Coordinating Council for Med-
ication Error Reporting and Prevention (NCC
MERP) scheme (see table I),[24] while causal re-
lationship between the medication error and an
adverse event was assessed using the simplified
Yale algorithm.[25] This procedure was followed
for all medication errors that reached the pa-
tient (i.e. at least NCC MERP class B)[26] The
causal relationship could be assessed as unlikely
(score <0), possible (score ‡0 and £3) and prob-
able (score = 4) [see table II]. In the case of poss-
ible or probable, the event was defined as a
pADE. When the relationship was unlikely, the
medication error was categorized as not asso-
ciated with a pADE. All assessments were achieved
through consensus agreement (JvD, RZ, PvdB,
Table I. National Coordinating Council for Medication Error Reporting and Prevention[24] scheme for medication error (ª 2001 National
Coordinating Council for Medication Error Reporting and Prevention. All Rights Reserved)
Category Description
A Circumstances or events that have the capacity to cause error
B An error occurred but the error did not reach the patient
C An error occurred that reached the patient but did not cause patient harm
D An error occurred that reached the patient and required monitoring to confirm that it resulted in no harm to the patient and/or
required intervention to preclude harm
E An error occurred that may have contributed to or resulted in temporary harm to the patient and required intervention
F An error occurred that may have contributed to or resulted in temporary harm to the patient and required initial or prolonged
hospitalization
G An error occurred that may have contributed to or resulted in permanent patient harm
H An error occurred that required intervention necessary to sustain life
I An error occurred that may have contributed to or resulted in the patient’s death
Table II. Simplified Yale algorithm (adapted from Kramer et al.,[25] with permission from the American Medical Association)
+1 0 -1 Score
Axis 1 Adverse event is well accepted as
ADR to suspected drug
Adverse event is not well
known or drug is new
Adverse event is previously unreported
as ADR to well known drug
Axis 2 (a) No good alternative candidate (score +2)
(b) Otherwise unexplained exacerbation or
recurrence of underlying illness (score +1)
Alternative candidate(s)
exist, but no good ones
Good alternative candidate(s) exist




Timing inconsistent for ADR for this
adverse event drug pair (score -2)
Total scorea
a Score <0 means ADR is unlikely; score ‡0 and £3 means ADR is possible and score= 4 means ADR is probable.
ADR = adverse drug reaction.
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JK and PM). This two-step procedure for iden-
tifying pADEs as described here, by combin-
ing the NCC MERP and Yale algorithms, has
been validated and described in detail elsewhere
previously.[26]
ADRs
In a separate procedure, the association be-
tween recorded possible adverse events not clas-
sified as pADEs and any drug taken by the patient
was assessed. The causal relationship between the
drug and an adverse event was assessed again using
the simplified Yale algorithm (table II)[25] with the
same cut-offs for unlikely, possible or probable
relationship with medication used. The possibly-
and probably-related adverse events were classi-
fied as ADRs. All assessments were made by two
reviewers in consensus. If more than one drug
had a possible/probable relation with an adverse
event, the adverse event was ascribed to the drug
with the highest Yale score.
In this study, the umbrella term ADE is used
when we refer to both pADEs and ADRs.
Determinants of pADEs and ADRs
Determinants for pADEs and ADRs included
in the study were organizational characteristics
(hospital, ward), patient characteristics (sex, age,
length of stay), drug-related characteristics (num-
ber of medication orders and drug type) and
a patient’s clinical condition. Determinants were
selected based on those being previously re-
ported.[5,7-11] We used multimorbidity, i.e. the
total number of diagnoses, to describe a patient’s
clinical condition, and hypothesized that a higher
number of diagnoses would make patients more
vulnerable to experiencing a pADE or ADR.
Data Analysis
Data were processed using Microsoft Access
2003 (Microsoft Corporation, Redmond, WA,
USA). Analysis was performed with SPSS ver-
sion 16.0 (SPSS Inc., Chicago, IL, USA). Uni-
variate analysis followed by multivariate analysis
was performed using a logistic regression (forced
entry) model to establish which determinants
independently contributed to the probability of
pADEs and ADRs. The model included all
determinants from the univariate analysis with a
p-value < 0.1. Crude and adjusted odds ratios
(ORs) with 95% CIs were calculated. In two
models, patients with one or more pADEs (model
1) and ADRs (model 2) were compared sepa-
rately to patients not experiencing ADEs. Length
of stay (days), age (years), number of medication
orders and number of diagnoses were analysed as
continuous variables.
Results
During the study period 609 patients were
admitted to the study wards, of whom six (ap-
proximately 1%) refused to take part in the study.
Overall, 349 (58%) of 603 hospitalized patients
experienced one or more ADE. A causal relation-
ship of the event with a medication error (pADE)
was established for 42 (12%) patients (7% of the
total population studied). The remaining 307
(88%) patients with an ADE (51% of the total
population studied) were classified as patients
experiencing an ADR (figure 1).
These 349 patients experienced 935 ADRs
(14% of these were WHO critical terms) and 54
pADEs (20% of these were WHO critical terms),
an average of almost three events per patient. The
most common ADRs and pADEs were constipa-
tion, diarrhoea, dyspnoea, increased interna-
tional normalized ratio (INR), nausea, dizziness
and fall. Of these common adverse events, INR
increase is considered by the WHO as critical
and, as such, warrant specific attention. Other
‘critical term’ pADEs or ADRs experienced by
patients were hyperkalaemia, hypoglycaemia,
phlebitis and hallucination (table III).
Themost common drugs related to both pADEs
and ADRs were drugs affecting the nervous sys-
tem (ATC code N), drugs for the cardiovascular
system (ATC code C), anti-infectives for systemic
use (ATC code J) and drugs affecting the blood
and the blood-forming organs (ATC code B)
[table IV]. Patients with pADEs commonly received
drugs for the nervous system, drugs affecting the
blood and the blood-forming organs, cardiovas-
cular drugs and systemic anti-infectives. Drugs
Prevalence and Determinants of Inpatient Adverse Drug Events 1093
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for the alimentary tract and metabolism (ATC
code A) were the third most frequent cause of
ADRs, but were infrequently related to pADEs.
The continuous variables, multimorbidity, length
of stay and number of medication orders, were
significant determinants for both pADEs (multi-
morbidity [ORadj 1.90; 95% CI 1.44, 2.50], length
of stay [ORadj 1.13; 95%CI 1.06, 1.21], number of
medication orders [ORadj 1.25; 95% CI 1.16, 1.35])
and ADRs (multimorbidity [ORadj 1.28; 95% CI
1.14, 1.45], length of stay [ORadj 1.11; 95% CI
1.07, 1.16] and number of medication orders [ORadj
1.13; 95% CI 1.06, 1.21]) [table V]. Admission to
the geriatric ward led to an increased risk of both
pADEs and ADRs (ORadj 7.78; 95% CI 2.15,
28.13 and ORadj 3.82; 95% CI 1.73, 8.45), and
admission to the gastroenterology/rheumatology
ward to a lower risk of both pADEs and ADRs
(ORadj 0.22; 95% CI 0.06, 0.77 and ORadj 0.40;
95% CI 0.24, 0.65). Other significant determi-
nants for ADRs only were female sex (ORadj 1.77;
95% CI 1.12, 2.80) and use of drugs affecting the
nervous system (ORadj 1.83; 95% CI 1.09, 3.07)
leading to an increased risk. In the multivariate
model, age (ORadj 1.07; 95% CI 1.03, 1.11) was a
significant determinant for pADEs only (table V).
As only 42 patients experienced a pADE, we re-
stricted our adjustment in model 1 (no ADE vs
pADE) to a maximum of three determinants (in
addition to the determinant of interest. There-
fore, we adjusted each determinant only for the
number of medication orders, ATC class B type
of drugs, and multimorbidity. This selection was
based, in part, on the literature, with ADEs most
firmly linked to the number of medication or-
ders[16] and ATC class B drugs (including anti-
coagulants, especially to pADEs),[18] and in part
to the strong univariate relation with a pADE
observed in our study. Multimorbidity is our de-
terminant of special interest; again, it was also
strongly related to pADEs in the univariate anal-
ysis and was thus selected.
Of note, in model 2 (no ADE vs ADRs) we
included all determinants that were significant in
the univariate analysis. In our sensitivity ana-
lyses, we performed the same analysis for model 1
(no ADE vs pADE) with age instead of ATC
class B drugs, and for model 2 (no ADE vs ADR)
we performed the same analysis but adjusted for
these three determinants: number of medication
orders, ATC class B type of drugs and multi-
morbidity. These sensitivity analyses resulted in
only minimal changes in point estimates and their
CIs (data not shown), except in two cases: one
determinant became just not significant, gastro-
enterology ward (ORadj 0.29; 95% CI 0.08, 1.06)
for pADE, and one became just significant, age
(ORadj 1.01; 95% CI 1.00, 1.02) for ADR.
Discussion
In our study, 58% of patients experienced one
or more ADEs, an average of three per patient.













Fig. 1. Description of the study population. ADE= adverse drug event; ADRs =adverse drug reactions.
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(51% of all patients). Only 7% of all patients
experienced an ADE that was caused by a med-
ication error (pADE). This situation occurred
after CPOE was installed, which had reduced
medication errors significantly, as shown in our
previous study that focused on preventable harm.[4]
Determinants of both ADRs and pADEs overlap
to a considerable extent (i.e. multimorbidity,
length of stay, number of medication orders, and
admission to geriatric and gastroenterology/
rheumatology wards). In addition, female sex
and drugs for the nervous system were determi-
nants for ADRs, and age was a determinant for
pADEs.
Themost commonpADEs orADRs experienced
by patients were constipation, diarrhoea, dyspnoea,
increased INR, nausea and dizziness, as well as
falls. Although most of these observed events
were non-serious, they affected patients’ quality
of life and stand as signals to problems that need
intervention. Increased INR is considered a ‘cri-
tical term’ by WHO standards, i.e. an adverse
event warranting follow-up. In a hospital setting,
these events and others such as abnormal labor-
atory values, could be addressed promptly, and
are typical examples of where more advanced in-
formation technology-centred solutions (CPOE
with CDSS) could be of value.
In our study, and after implementation of a
CPOE system, hospitalized patients primarily
experienced ADEs that were not caused by med-
ication errors (i.e. ADRs). This implies that basic
CPOE systems are not enough to prevent ADRs
since they focus primarily on detecting medication
errors, e.g. DDI or overdosage. A similar high
rate in ADRs versus pADEs was observed in a
hospital setting where a medication review by
pharmacists had led to a reduction in pADEs but
where no effect was observed on ADRs.[5,27]
In contrast to recent reviews on ADEs in
hospitalized patients, the proportion of patients
with ADEs is high in our study. This difference
could be explained by the fact that these re-
views focused on serious, life-threatening or fatal
ADEs,[10,17] whereas in this study we also included
non-serious ADEs. Our data collection included
review of often overlooked nurses’ charts, which
are considered a good source for less serious
ADEs such as nausea, rash or changes in mental
status. Nurses are in closest contact with patients
and their relatives and are informed first of any
complaints and observations they may have.[28]
We think that such events, from the perspective
of the hospitalized patient, are very important
and can negatively affect their well-being, and
should thus receive appropriate attention. Although
themajority of these ADEsmay not be preventable,
Table III. Most common adverse drug eventsa




Constipation 8 (14.8) 68 (7.3)
Diarrhoea 4 (7.4) 67 (7.2)
Headache 0 (0.0) 52 (5.6)
Nausea 3 (5.6) 45 (4.8)
Oedema 0 (0.0) 45 (4.8)
Sedation 0 (0.0) 38 (4.1)
Agitation 0 (0.0) 35 (3.7)
Dyspnoea 5 (9.3) 31 (3.3)
Dizziness 2 (3.7) 25 (2.7)
Fatigue 0 (0.0) 21 (2.2)
Confusion 0 (0.0) 19 (2.0)
Hyperglycaemia 0 (0.0) 19 (2.0)
Hypotension 0 (0.0) 19 (2.0)
Fall 2 (3.7) 17 (1.8)
Hypoglycaemiab 0 (0.0) 17 (1.8)
Pain 0 (0.0) 17 (1.8)
Sleep difficult 0 (0.0) 17 (1.8)
Abdominal pain 0 (0.0) 13 (1.4)
Disorientation 0 (0.0) 13 (1.4)
Phlebitisb 0 (0.0) 12 (1.3)
Emesis 0 (0.0) 11 (1.2)
INR increasedb 4 (7.4) 10 (1.0)
Hallucinationb 0 (0.0) 10 (1.0)
Haematoma 2 (3.7) 3 (0.3)
Hyperkalaemiab 2 (3.7) 2 (0.2)
Other 22 (40.7) 309 (33.0)
Totalc,d 54 (100) 935 (100)
a Adverse drug events were classified according to the WHO
Adverse Reactions Terminology.[22]
b These ADEs are WHO critical terms.
c Percentages do not sum exactly to 100% because of rounding.
d The number of pADEs and ADRs are higher than the total
number of patients as some patients experienced more than one
event.
ADR = adverse drug reaction; INR = international normalized ratio;
pADE = preventable adverse drug event.
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a number of them could be managed at an early
stage by, for example, stopping or switching to a
different drug, adapting a dose, or sometimes
adding a drug to alleviate symptoms.
Detection of ADEs and medication errors is
also known to be influenced by the way the
data are collected and reviewed.[29] Prospective/
retrospective chart review, spontaneous report-
ing and use of trigger tools are shown to generally
identify different ADEs. Among these methods,
prospective methods have been shown to be the
more sensitive strategy for detecting ADEs com-
pared with retrospective review.[30] Moreover,
an intensive, prospective, frequent chart review,
such as the one we performed, consistently iden-
tifies the highest number of ADEs and med-
ication errors.[29] Lastly, we used a low threshold
for causal relationship between the adverse eve-
nts and medication, i.e. we considered an adverse
event as being drug-related when it had a possible
or probable relationship with the drug taken. A
study by Nebeker et al.[5] found a similar rate of
ADEs per admission as to that found in our
study; however, their CPOE was even more basic
than ours, lacking dosing or interaction control,
thus translating into a higher proportion of
pADEs than we observed. The daily ward visits
by the research pharmacists may have had a
slight impact on the reporting of adverse events,
which may have been higher due to their aware-
ness of drug-related issues. Other staff on the
wards may also have been made more aware of
drug issues and the potential for ADEs because
of the daily ward visits by the research pharma-
cists. However, we expect this to be minimal as in
our hospitals many different staff members, in-
cluding researchers, frequently visit the wards.
We identified approximately the same deter-
minants for pADEs and ADRs as reported else-
where: number of medication orders, length of
hospital stay, organizational characteristics (ger-
iatric ward increases and gastroenterology/
rheumatology ward decreases risk)[14,15,31] and
also multimorbidity.[32,33] The role of drug classes
was less pronounced, with some exceptions. Drugs
for the nervous system (ATC group N) increased
and those grouped under ‘Others’ decreased the
risk for ADRs only, but no drug class was a de-
terminant for pADEs in the multivariate anal-
yses. This underlines the relevance of closely
Table IV. Most commonly prescribed drugs for patients with adverse drug eventsa
ATC code Drug class pADE [no. of events (%)] ADR [no. of events(%)]
A Alimentary tract and metabolism 1 (1.9) 141 (15.1)
B Blood and blood-forming organs 11 (20.4) 61 (6.5)
C Cardiovascular system 8 (14.8) 214 (22.9)
D Dermatological 0 (0.0) 1 (0.1)
G Genito-urinary system and sex hormones 0 (0.0) 9 (1.0)
H Systemic hormonal preparations, excluding sex hormones and insulins 0 (0.0) 33 (3.5)
J Anti-infectives for systemic use 7 (13.0) 97 (10.4)
L Antineoplastic and immunomodulating agents 0 (0.0) 10 (2.6)
M Musculo-skeletal system 5 (9.3) 33 (3.5)
N Nervous system 17 (31.5) 298 (31.9)
P Antiparasitic products, insecticides and repellents 0 (0.0) 5 (0.5)
R Respiratory system 5 (9.3) 31 (3.3)
S Sensory organs 0 (0.0) 2 (0.2)
Totalb,c 54 (100) 935 (100)
a Relationships in terms of frequencies and percentages of ADRs or pADEs with the most commonly used drugs (classified by the first
character of their ATC code) are given in this table.
b Percentages do not sum exactly to 100% because of rounding.
c The number of pADEs and ADRs are higher than the total number of patients as some patients experienced more than one event.
ADR = adverse drug reaction; ATC =Anatomical Therapeutic Chemical; pADE = preventable adverse drug event.
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Table V. Risk factors for patients with preventable adverse drug event (pADE) and adverse drug reaction (ADR) vs no adverse drug event (ADE)
Determinantsa No ADE
[n (%)] (n =254)
Model 1b Model 2b
pADE [n (%)]
(n =42)
OR (95% CI) ORadjc (95% CI) ADR [n (%)]
(n =307)
OR (95% CI) ORadjd (95% CI)
Sex
male 127 (50.0) 17 (40.5) Ref (ref) Ref (ref) 118 (38.4) Ref (ref) Ref (ref)
female 127 (50.0) 25 (59.5) 1.47 (0.76, 2.86) 1.20 (0.48, 2.99) 189 (61.6) 1.60 (1.14, 2.24) 1.77 (1.12, 2.80)
Age (mean –SD)e 58.7 (19.03) 77.6 (10.7) 1.09 (1.06, 1.13) 1.07 (1.03, 1.11) 68.7 (18.4) 1.03 (1.02, 1.04) 0.99 (0.98, 1.01)
Hospital department
internal medicine 99 (39.0) 17 (40.5) Ref (ref) Ref (ref) 119 (38.8) Ref (ref) Ref (ref)
gastroenterology/rheumatology 144 (56.7) 5 (11.9) 0.20 (0.70, 0.57) 0.22 (0.06, 0.77) 84 (27.4) 0.48 (0.33, 0.71) 0.40 (0.24, 0.65)
geriatric 11 (4. 3) 20 (47.6) 10.60 (4.31, 25.98) 7.78 (2.15, 28.13) 104 (33.9) 7.87 (4.00, 15.47) 3.82 (1.73, 8.45)
Length of stay (mean –SD)e 6.13 (5.3) 20.8 (17.2) 1.21 (1.15, 1.28) 1.13 (1.06, 1.21) 15.84 (12.2) 1.20 (1.15, 1.24) 1.11 (1.07, 1.16)
Multimorbidity (mean –SD)e 3.13 (1.63) 4.8 (1.6) 1.72 (1.41, 2.11) 1.90 (1.44, 2.50) 4.03 (1.95) 1.32 (1.20, 1.46) 1.28 (1.14, 1.45)
Number of medication orders
(mean –SD)e
7.1 (4.9) 18.2 (9.2) 1.29 (1.20, 1.39) 1.25 (1.16, 1.35) 14.7 (9.3) 1.21 (1.16, 1.25) 1.13 (1.06, 1.21)
Type of drug (ATC code)
Alimentary tract and metabolism (A) 185 (72.8) 38 (90.5) 3.54 (1.22, 10.30) 0.37 (0.09, 1.48) 268 (87.3) 2.56 (1.66, 3.96) 1.06 (0.56, 2.03)
Blood and blood-forming organs (B) 130 (51.2) 37 (88.0) 7.06 (2.69, 18.54) 2.33 (0.71, 7.59) 231 (75.2) 2.90 (2.03, 4.14) 1.20 (0.73, 1.98)
Cardiovascular system (C) 130 (51.2) 31 (73.8) 2.69 (1.30, 5.58) 0.67 (0.23, 1.91) 224 (72.3) 2.57 (1.18, 3.66) 1.00 (0.60, 1.71)
Anti-infectives for systemic use (J) 84 (33.1) 23 (54.8) 2.45 (1.26, 4.75) 0.90 (0.36, 2.30) 156 (50.8) 2.09 (1.48, 2.95) 1.12 (0.69, 1.82)
Nervous system (N) 133 (52.4) 35 (83.3) 4.55 (1.95, 10.62) 2.58 (0.86, 7.79) 257 (83.7) 4.68 (3.16, 6.91) 1.83 (1.09, 3.07)
Others 145 (57.1) 36 (85.7) 4.51 (1.84, 11.09) 0.88 (0.27, 2.89) 208 (67.8) 1.58 (1.12, 2.23) 0.55 (0.33, 0.92)
a Determinants influencing the prevalence of ADR vs no ADE and determinants influencing the prevalence of pADE vs no ADE were determined for their significance based on the
values of the crude and adjusted ORs with their 95% CI. Values in bold are statistically significant.
b Analysed vs no ADE.
c Adjusted for multimorbidity, ATC code B type of drugs (Blood and blood-forming organs) and number of medication orders.
d Adjusted for all other variables.
e Analysed as a continuous variable.











































































monitoring patients with multiple morbidities to
identify ADRs and pADEs that may be man-
ageable (e.g. symptomatic treatment or drug dis-
continuation). Age was a risk factor for pADE
but was significant in a sensitivity analysis for
ADRs also, stressing the fact that the elderly
should receive appropriate attention because they
are a vulnerable population who often have
multiple co-morbidities for which they receive
multiple drugs.[34]
This study confirms findings from other stud-
ies that women have a greater risk of developing
ADRs compared with men, and this may be ex-
plained by intrinsic differences in pharmacokinetic,
immunological, hormonal and behavioural sex-
related factors.[35,36] However, it is unclear to us,
in this study, why women were not more prone to
be harmed when an error in the medication pro-
cess was made. The observation that more non-
preventable ADRs were identified in patients
admitted to a geriatric ward could be explained
by an increased awareness of medical, nursing
and pharmacy staff that frail elderly patients in
particular may be more vulnerable to medication
harm.[37,38]
At present, interventions in hospital processes
focus primarily on reducing medication errors
and pADEs, but our study shows that this may
need to change to ensure ADRs are also managed.
The current focus on Information and Commu-
nications Technology (ICT) solutions through
CPOE and CDSS, even when addressing risk
factors common to pADEs and ADRs, will not
suffice in ameliorating the large proportion of
medication-related patient harm that is not
captured in a structured manner (e.g. laboratory
results) in the hospital information system. In-
creased attention on the early detection of patient
harm is of paramount importance in view of the
frequent occurrence of non-preventable ADRs.
ICT systems are not yet able to detect these non-
preventable ADRs comprehensively. Hospital staff
directly attending the patient, with a possible role
for the clinical pharmacist, should pay more at-
tention to medication safety. Early identification
and management of these non-preventable ADRs,
even when considered minor compared with the
reason for admission, may contribute considerably
to the well-being of an inpatient. This may need
further research, for example, into protocols for
nursing staff to raise awareness of minor ADRs
and to systematically check for potentially man-
ageable medication harm.
This study has some limitations. Only patients
from gastroenterology, rheumatology, geriatrics
and general internal medicine wards of two hos-
pitals were included in this study; therefore, our
results may not apply to other departments or
other hospitals. For example, time constraints in
the emergency department and hierarchical struc-
tures in surgical teams have been shown to ne-
gatively affect handling of patient safety issues
compared with an internal medicines setting.[39]
Furthermore, our study only considered pre-
scribing and transcribing errors and did not in-
clude errors made when administering medication
to patients. We used a sensitive and low threshold
approach for detecting ADEs that may explain
our observed high incidence of ADEs. In clinical
practice it is not feasible to perform a full caus-
ality assessment using, for example, the complete
Yale algorithm. The recognition that patients
experience many discomforting ADEs while in
hospital, albeit not caused by medication errors,
could, nevertheless, be of considerable importance
from the patient’s perspective as they may be
manageable. A strong point of our study is the
method of detection of ADEs. This study pro-
spectively reviewed charts daily, which has been
previously described as an effective strategy for
detecting ADEs compared with a retrospective
approach.[23]
Conclusions
Our study shows that ADEs are a frequent
problem in hospitalized patients. Most interven-
tions in hospital processes (CPOE/CDSS and/or
medication review) target pADEs, but the ma-
jority of ADEs are not preventable, even when a
CPOE is in place. Our study also shows that de-
terminants are to a large extent similar for both
preventable ADEs and non-preventable ADRs.
Signalling early potential adverse events that occur
during the normal use of drugs in multimorbid pa-
tients and subsequent therapeutic interventions
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may improve the well-being of hospitalized pa-
tients to a greater extent than focusing on errors
in the medication process only. Aside from the
more commonly known determinants, our study
confirmed that multimorbidity is associated with
an increased risk of pADEs and ADRs, suggest-
ing that it is important to identify high-risk
patients who need close monitoring for early de-
tection of these events.
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